A company that's taking a new approach to tackling Alzheimer's just landed a $225 million endorsement
AP/Alastair Grant
- Biotech startup Alector just got a $225 million endorsement from pharma giant AbbVie for its work in neurodegenerative diseases.
- Alector's developing treatments that harness the body's immune system to tackle conditions like Alzheimer's, and other forms of dementia.
- The work's still in its early stages, but Alector's hoping to get five treatments into human trials in the next two years.
A startup that's trying to harness the body's immune system to treat neurologic diseases like Alzheimer's just got a major endorsement from pharma giant AbbVie.
As part of the deal, Alector gets a $205 million upfront payment and a future equity investment that's up to $20 million, with AbbVie having the option to globally develop and commercialize two of the drug targets. Up to this point, Alector had raised $80 million from Orbimed, GV, Polaris along with pharmaceutical companies including Merck, Amgen, and AbbVie's venture arm.
The approach of using the body's immune system to treat a particular disease has so far proven successful in the field of cancer, where it's known as immuno-oncology. It's led to remarkable remissions in some patients, along with some first-of-its kind approvals. Alector's hoping to have similar success in building out the field of "immuno-neurology."
"It's really something that's just emerging," Alector CEO Arnon Rosenthal told Business Insider. Alector's looking for treatments that target the body's innate immune system, using the genetic markers associated with neurodegenerative conditions like Alzheimer's disease and ALS. That information wasn't available five years ago, Rosenthal said.
It's because of that genetic information that scientists have come to better understand the link between the immune system and Alzheimer's. The hope is that by more broadly going for immune system, the treatments might have a better shot at working than more targeted approaches that have had some setbacks in the past few years.
AbbVie is developing new treatments to treat neurodegenerative diseases, specifically one that targets the tau proteins that get tangled in the brain of people with Alzheimer's. Rosenthal said that ideally, these more targeted treatments could be used in combination with the immunotherapy approach Alector's going after.
"Alector's unique approach to engaging the immune system to combat neurodegeneration reflects our commitment to target this epidemic in new ways," Jim Sullivan, AbbVie's vice president of pharmaceutical discovery, said in a news release. "We recognized the potential of Alector's research first as an AbbVie Ventures portfolio company and are now eager to partner with them to further develop this platform into meaningful advances for patients."
It's still in early stages, but Alector is hoping to get five drug targets into human trials over the next two years. To start, that's going to include targets for Alzheimer's and another common form of dementia called frontotemporal dementia.
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- A centenarian who starts her day with gentle exercise and loves walks shares 5 longevity tips, including staying single
- 2 states where home prices are falling because there are too many houses and not enough buyers
- "To sit and talk in the box...!" Kohli's message to critics as RCB wrecks GT in IPL Match 45
- 7 Nutritious and flavourful tiffin ideas to pack for school
- India's e-commerce market set to skyrocket as the country's digital economy surges to USD 1 Trillion by 2030
- Top 5 places to visit near Rishikesh
- Indian economy remains in bright spot: Ministry of Finance
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market